BioSpace News Archive

Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

Junshi Biosciences (HKEX: 1877; SSE: 688180), announced today that the National Medical Products Administration (NMPA) of China has accepted an investigational new drug application for UBP1213sc, its subcutaneous injection of recombinant humanized anti-BLyS monoclonal antibody.

August 26, 2021
·
3 min read
Business

Patterson Companies Fiscal 2022 First-Quarter Conference Call Scheduled for Thursday, September 2, 2021

Patterson Companies announced that it will hold its fiscal 2022 first-quarter conference call on Thursday, September 2, 2021 at 7:30 a.m. CT.

August 26, 2021
·
1 min read
Drug Development

Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer

Laekna Therapeutics announced that the Center for Drug Evaluation, the National Medical Products Administration of China has approved the Investigational New Drug application of its Category 1 new drug candidate afuresertib in combination with anti-estrogen receptor drug fulvestrant in the Phase Ib/III clinical trial of patients with locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

August 26, 2021
·
5 min read